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QTcI interval ≥60 ms, and one patient had a QTcI interval 
>500 ms following multiple-dose TAS-102 administration. 
No patient had an uncorrected QT, QTcF, or QTcB interval 
>500 ms. Based on the exposure-response analysis between 
TAS-102 plasma concentrations and the placebo-adjusted 
QTc intervals, none of the upper bounds of the one-sided 
95 % prediction intervals exceeded 20 ms. There were no 
significant morphological changes for T or U waves. No 
cardiovascular AEs were reported in cycle 1. Across all 
cycles, no patient experienced an AE of ventricular tachy-
cardia, ventricular fibrillation, syncope, or seizure.
Conclusions There was no clinically relevant relationship 
between TAS-102 plasma concentrations and QTc inter-
val; TAS-102 had no clinically relevant effects on cardiac 
repolarization.
Clinical trials ClinicalTrials.gov study number: NCT 
01867879.
Keywords 5-Fluorouracil · Cardiac · QT interval ·  
TAS-102 · Tipiracil · Trifluridine
Introduction
Nucleoside inhibition has played an important role in the 
treatment of cancer. Notably fluoropyrimidines, including 
5-fluorouracil and its derivatives, have been an important 
class of medications used in oncology for decades [1].
TAS-102 is a novel oral agent that combines trifluridine 
(FTD), a thymidine-based nucleoside analogue, plus tip-
iracil hydrochloride (TPI), in a molar ratio of 1:0.5 [2, 3]. 
TPI has been shown to be a potent and specific inhibitor 
of thymidine phosphorylase in animal models and human 
tumor cells, and allows sustained FTD concentrations to be 
maintained after oral administration [4].
Abstract 
Purpose TAS-102 is a novel oral agent combining the 
antineoplastic thymidine-based nucleoside analogue, tri-
fluridine, and the thymidine phosphorylase inhibitor, tip-
iracil (molar ratio 1:0.5). TAS-102 has shown good activity 
in refractory metastatic colorectal cancer with acceptable 
safety. No QT prolongation was seen in clinical studies. 
This study aimed to investigate TAS-102 cardiac safety for 
regulatory requirements.
Methods This was a phase 1, non-randomized study in 
adults with advanced solid tumors. Intensive QT assess-
ments were conducted at baseline, placebo, and following 
single and multiple doses of TAS-102 during a 28-day cycle.
Results Following single- and multiple-dose administra-
tion (N = 30), the upper bounds of the one-sided 95 % 
confidence intervals for the difference between TAS-102 
and placebo in time-matched baseline-subtracted 12-lead 
Holter QT intervals did not exceed 20 ms at any prespeci-
fied time point. One patient had a change from baseline in 
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TAS-102 has been investigated in preclinical studies, 
with no identified effect on cardiac ventricular repolariza-
tion, using the in vitro hERG assay. Similarly, in conscious 
monkeys, TAS-102 showed no effects on blood pressure, 
heart rate, and electrocardiographic parameters at a dose 
that produced a maximum plasma concentration (Cmax) of 
FTD and TPI similar to that observed in humans with the 
anticipated clinical dose of TAS-102.
In humans, TAS-102 has been investigated in phase 1 
dose-finding and food-effect studies and clinical studies 
in patients with refractory metastatic colorectal cancer [3, 
5–7]. There has been no evidence of an effect of TAS-102 
on cardiac events in a phase 1 (N = 27) or phase 3 clinical 
study (N = 800) [6, 7].
The present study was conducted to investigate the 
effect of TAS-102 on cardiac repolarization after single-
dose and multiple-dose administration; to evaluate the car-
diac safety profile of TAS-102; and to evaluate the relation 




The study was a phase 1, non-randomized study, which was 
open-label except for a single, patient-blinded dose of pla-
cebo on the morning of day −1 to control for individual 
variability in electrocardiogram (ECG) responses. Given 
the cytotoxic nature of TAS-102, the design of the study 
was chosen to comply as closely as ethically possible to the 
International Conference on Harmonisation E14 Guideline 
(The Clinical Evaluation of QT/QTc Interval Prolonga-
tion and Proarrhythmic Potential for Non-antiarrhythmic 
Drugs) [8, 9]. Although not a true thorough QT/QTc study, 
the study included intensive QT assessments during a full-
time-matched baseline day and full-day assessments fol-
lowing administration of a single dose of placebo and sin-
gle and multiple doses of TAS-102.
The cardiac safety evaluation took place during cycle 1 of 
treatment over 28 days and was the first of two parts of the 
overall study. The second part was an extension phase con-
sisting of the same 28-day cycle, which was repeated until 
the patient met any of the treatment discontinuation criteria. 
Efficacy and safety assessments were performed during the 
second part of the study and are not included in this report, 
which only includes the cardiac safety results of cycle 1.
Endpoints
The primary endpoint was the time-matched difference in 
QTcI interval (the QT interval corrected for heart rate using 
a patient-specific correction) between TAS-102 and placebo 
at each time point. QTcI was determined as QTcI = QT/
RRβi, where βi is the patient-specific correction factor com-
puted from a log-linear model log(QT) = αI + βi x log(RR) 
using information obtained at baseline (day −2) from each 
individual patient i. Secondary endpoints were the relation 
between TAS-102 pharmacokinetics, and its effect on car-
diac repolarization and qualitative ECG changes from base-
line based on evaluation of 12-hour Holter recordings with 
extracted 12-lead ECG recordings.
Patient population
The study population consisted of male and female patients 
≥18 years of age with histologically or cytologically con-
firmed advanced solid tumors (other than breast cancer) 
for whom no standard therapy existed. Major inclusion 
criteria included having received ≤5 prior cytotoxic cancer 
therapies; Eastern Cooperative Oncology Group perfor-
mance status 0 or 1 on day −2; ability to take medications 
orally without a feeding tube; corrected QT interval using 
Bazett’s correction (QTcB) ≤450 ms on resting ECG; and 
adequate organ function.
Major exclusion criteria were major surgery or extended 
field radiation within 4 weeks; baseline heart rate >100 
beats per minute (bpm) or <50 bpm; extended field radi-
ation within 4 weeks or limited field radiation within 
2 weeks; any anticancer therapy within 3 weeks (mito-
mycin within 5 weeks); serious acute or chronic illness or 
medical or psychiatric condition(s) or laboratory abnormal-
ity that may have increased the risk associated with study 
participation or may have interfered with interpretation of 
study results; and concomitant use of a medication known 
to affect the QT interval or be arrhythmogenic.
The study was conducted, and informed consent was 
obtained, according to the ethical principles originating in 
the Declaration of Helsinki (2008) and in accordance with 
Title 21 CFR 312.50 through 312.70, the International 
Council for Harmonisation Harmonised Tripartite Guide-
lines for Good Clinical Practice, and local and national 
laws and regulations relevant to the use of investigational 
therapeutic agents. The protocol was approved by the local 
institutional review board.
Procedures
On day −1, the day prior to the first dose of TAS-102, all 
patients received a single, patient-blinded dose of placebo 
in the morning corresponding to a 35 mg/m2 dose of TAS-
102 based on body surface area (Fig. 1). On days 1 through 
5 and 8 through 12, patients received TAS-102 35 mg/m2 
twice daily within 1 h after completing a meal. On days 1 
and 12, the second dose of the day was administered 12 h 
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after the morning dose to allow for collection of a 12-hour 
pharmacokinetic sample.
Dose reductions for Grade ≥3 non-hematologic drug-
related toxicity were allowed in 5 mg/m2 steps to a mini-
mum dose of 20 mg/m2. The dose of TAS-102 was held for 
neutrophils <500/mm3 or platelets <50 000/mm3.
Twelve-hour Holter ECG recordings were obtained 
within 48 h prior to the first active dose of TAS-102 (day 
−2), as well as following administration of placebo on 
day −1 and TAS-102 on day 1 (single-dose) and day 12 
(multiple-dose). Twelve-lead ECG recordings were ana-
lyzed at 0, 15, and 30 min, and 1, 2, 4, 6, 8, 10, and 12 h 
postdose. At each time point, the following were meas-
ured: respiratory rate, pulse rate, QRS interval, heart rate, 
and uncorrected and corrected QT interval. Twelve-lead 
ECGs were obtained at screening and prior to the morn-
ing dose on days 1 and 12. Three 10-second 12-lead ECG 
tracings were extracted within a 5-minute period at each 
time point. The analysis included each of the three ECGs 
from a triplicate (three ECGs at each time point) as a single 
observation. Each of the three ECGs at a single time point 
was interpreted as normal or abnormal by a single, central, 
independent cardiologist blinded to treatment, time, and 
day. The global median beat was prespecified as the lead 
for interval measurements, and the same lead was used for 
baseline and postbaseline assessments.
Blood samples were collected approximately 5 min 
after the corresponding nominal time points for extraction 
of digital ECG data to measure plasma concentrations of 
TAS-102 components (FTD and TPI) and metabolite (trif-
luoromethyl-2,4(1H,3H)-pyrimidinedione [FTY]).
Statistics
Triplicate ECG values obtained at each time point were 
averaged for analysis of the primary endpoint. Descriptive 
statistics were provided at each time point for QTcI, QTcB, 
QTcF, QT, PR, QRS, and RR intervals, and heart rate for 
baseline (day −2) and days −1, 1, and 12, and the corre-
sponding change from baseline. For each postdose sched-
uled time point of ECG collection, the baseline-subtracted 
QTcI interval was analyzed using a repeated measure anal-
ysis of variance (ANOVA), separately for ECGs assessed 
during days 1 and 12 of TAS-102 dosing compared with 
placebo. The model includes the factors of treatment, 
time, and treatment by time interaction. The measurements 
within each patient’s treatment were treated as repeated 
measures. The compound symmetry covariance was used. 
The upper bounds of the one-sided 95 % confidence inter-
val and the point estimate were obtained for the differ-
ences in time-matched baseline-subtracted QTc between 
TAS-102 and placebo, separately for day 1 and day 12. 
Similar ANOVA models were applied to analyze QTcF and 
QTcB intervals. The non-inferiority margin for this study 
was 20 ms. A sequential test procedure was used to assess 
whether the placebo-corrected, time-matched differences 
in QTc exceeded 20 ms at any time point on days 1 and 
12. The required parameter and intra-patient error term 
standard deviation (12.3 ms) were adopted from Zhang 
et al. to compute the sample size [10]. If the true difference 
in the QTcI between TAS-102 and placebo was ≤5 ms at 
all measurement time points, 30 evaluable patients would 
ensure at least 90 % power to conclude that TAS-102 was 
non-inferior to placebo with respect to the effect on QTcI 
interval prolongation at a 5 % significance level.
The number and percentage of patients having maxi-
mum changes from baseline in the categories of <20, ≥20 
and <30, ≥30 and <60, and ≥60 ms were presented for the 
following ECG parameters: QTcI, QTcF, and QTcB by 
time point for each assessment day. A similar tabulation 
was provided for the maximum individual postdose abso-
lute value in the categories of >450 and ≤480 ms, >480 
Fig. 1  Study design of cardiac 
safety evaluation. ICH, Interna-
tional Council for Harmonisa-
tion; PK pharmacokinetics
CARDIAC SAFETY EVALUATION 
Cycle 1 (TAS-102 35 mg/m2 bid)




Up to a maximum 
of 28 days 
Baseline Assessment 
ICH signed Day -2 Day -1 Day 1 Days 2-5 Days 6-7 Days 8-11 Day 12 Days 13-28 
Confi eligibility/enrollment
PK Blood Sampling 
12-hour Holter Monitoring
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and ≤500 ms, and >500 ms. The number and percentage of 
patients with normal or abnormal findings for T wave and 
U wave were summarized. The relation between plasma 
concentrations of TAS-102 and the change from baseline 
in QTc adjusted by placebo was quantified using a linear 
mixed-effect model approach. All patients who had paired 
ECG and plasma concentrations for FTD, FTY, and TPI 
were included in the analysis.
Results
Disposition of subjects
A total of 66 patients signed informed consent, of which 
22 failed to meet eligibility criteria. The 44 patients who 
were treated comprise the safety population. Fourteen of 
the 44 patients were excluded, leaving 30 to comprise the 
cardiac safety study population. Reasons for exclusion 
were missing and/or inadequate ECG data (9), taking a pro-
hibited medication (3), low baseline electrolytes that may 
have affected QT time (2), and missed or reduced drug dos-
ing/non-compliance (1); one patient had two reasons for 
exclusion. The demographic and baseline characteristics 
of the safety and cardiac safety populations were similar 
(Table 1).
The cardiac safety population consisted of all patients 
who took part of any dose of the study treatment and who 
had at least 50 % time-matched triplicate ECG measure-
ments on days −2, −1, 1, and 12. Patients could not have 
taken prohibited concomitant medications, missed or 
reduced doses of TAS-102, not been <100 % compliant 
with TAS-102, or had a major protocol deviation. The car-
diac safety population was utilized for analysis of all QTc 
data.
The median dose intensity was 162.30 mg/m2/week and 
the median relative dose intensity, i.e., the ratio of actual 
dose intensity to planned dose intensity, was 0.93.
QT interval
QTcI
The upper bounds of the one-sided 95 % confidence inter-
vals for the differences in time-matched, baseline-sub-
tracted, 12-lead ECG QTcI intervals between TAS-102 and 
placebo did not exceed 20 ms at any time point following 
single-dose (day 1) or multiple-dose (day 12) administra-
tion of TAS-102 (Table 2; Fig. 2). 
Two patients accounted for the changes from baseline 
in QTcI interval ≥30 ms, one on day −1 and the other 
at all postdose time points on day 12. One patient had a 
QTcI interval of 506 ms on a single ECG tracing 4 h after 
dosing on day 12. The second and third tracings of the pro-
tocol-required triplicate tracing were inadequate due to low 
T-wave amplitude. QTcI intervals on individual tracings at 
all other study time points were ≤500 ms.
QTcF and QTcB
The upper bounds of the one-sided 95 % confidence inter-
vals for the differences in time-matched, baseline-sub-
tracted 12-lead ECG QTcF and QTcB intervals between 
TAS-102 and placebo also did not exceed 20 ms at any 
time point on either day 1 or day 12. One patient with a 
QTcI interval of 506 ms at 4 h postdose on day 12 had 
a QTcB interval >480 to ≤500 ms at this time point. All 
other QTcF, QTcB, and uncorrected QT intervals were 
≤480 ms for all patients. No patient had a QTcF, QTcB, or 
uncorrected QT interval >500 ms at any time point.
Four patients had a change from baseline in QTcF inter-
val of ≥30 to <60 ms following multiple-dose administra-
tion of TAS-102; five patients had a change from baseline 
in QTcB interval ≥30 to <60 ms (two following placebo 
administration and three following multiple-dose admin-
istration of TAS-102). Changes from baseline in uncor-
rected QT intervals of ≥30 to <60 ms were noted for seven 
patients following placebo administration and six patients 
each following single-dose and multiple-dose administra-
tion of TAS-102. One patient had a change from baseline in 
uncorrected QT interval ≥60 ms following placebo admin-
istration. All other changes from baseline in QTcF, QTcB, 
and uncorrected QT intervals were <30 ms for all patients.
No significant morphological changes were observed 
at any time point following placebo administration or sin-
gle- or multiple-dose administration of TAS-102. Overall, 
no difference in ECG waveform results was observed with 
administration of TAS-102 compared with administration 
of placebo. All T waves and U waves were assessed as nor-
mal for all patients.
Plasma pharmacokinetics and QTc relation
All 44 patients in the safety population were included in 
the pharmacokinetic evaluable population for day 1. For 
day 12, four patients were excluded due to missing assays 
(2), prohibited concomitant medication (1), or withdrawal 
of consent (1). Data for the 12-hour time points on days 1 
and 12 were excluded for five patients because it appeared 
that the patients may have received a subsequent dose of 
TAS-102 before the 12-hour sampling time point.
Following single-dose administration of TAS-102, the 
FTD plasma concentration reached a maximum approxi-
mately 2 h after dosing and declined with an elimination 
half-life of approximately 1.5 h (Fig. 3). On day 12, Cmax of 
FTD increased approximately twofold and the area under 
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Table 1  Demographic and 
baseline characteristics of the 
cardiac safety population
Parameter Safety population (n = 44) Cardiac safety population (n = 30)
Age, year
 Mean 59.0 58.9
 SD 8.86 8.10
 Median 59.0 58.0
 Minimum, maximum 39, 78 41, 77
Gender, n (%)
 Male 22 (50.0) 15 (50.0)
 Female 22 (50.0) 15 (50.0)
Race, n (%)
 White 38 (86.4) 26 (86.7)
 Black, of African heritage 3 (6.8) 2 (6.7)
 Asian 2 (4.5) 2 (6.7)
 American Indian or Alaskan Native 1 (2.3) 0
Ethnicity, n (%)
 Hispanic or Latino 1 (2.3) 1 (3.3)
 Not Hispanic or Latino 43 (97.7) 29 (96.7)
Body surface area, m2
 Mean 1.92 1.91
 SD 0.283 0.253
 Median 1.91 1.88
 Minimum, maximum 1.44, 2.66 1.48, 2.34
ECOG performance status, n (%)
 0 29 (65.9) 21 (70.0)
 1 15 (34.1) 9 (30.0)
Cancer type, n (%)
 Cervical 2 (4.5) 1 (3.3)
 Colon 32 (72.7) 23 (76.7)
 Rectal 1 (2.3) 1 (3.3)
 Esophageal 2 (4.5) 0
 Pancreatic 3 (6.8) 3 (10.0)
 Renal 2 (4.5) 1 (3.3)
 Uterine 1 (2.3) 0
 Other 1 (2.3) 1 (3.3)
Prior surgery/biopsy related to cancer,a n (%)
 Yes (excludes patients with biopsy  
only)
35 (79.5) 23 (76.7)
  Primary 27 (61.4) 16 (53.3)
  Other 19 (43.2) 13 (43.3)
 Biopsy 34 (77.3) 24 (80.0)
 No 0 0
Prior radiotherapy
 Yes 18 (40.9) 12 (40.0)
 No 26 (59.1) 18 (60.0)
Prior systemic cancer therapy,b n (%)
 Yes 44 (100) 30 (100)
Intent of prior systemic cancer therapy,a n (%)
 Neoadjuvant 8 (18.2) 5 (16.7)
 Adjuvant 15 (34.1) 8 (26.7)
 Metastatic 40 (90.9) 28 (93.3)
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the concentration-time curve from hour 0 to the time of 
last measurable plasma concentration (AUC0–last) increased 
approximately threefold compared with those on day 1, 
suggesting an increase in the bioavailability and a decrease 
in the clearance of FTD after multiple-dose administration 
of TAS-102. Plasma concentration-time profiles of FTY 
and TPI were generally similar to those of FTD.
The slope between the placebo-adjusted change from 
baseline in QTcI interval and pharmacokinetic concentra-
tions for FTD and TPI was positive as observed from the 
linear mixed-effect model. However, none of the upper 
bounds of the one-sided 95 % prediction intervals at mean 
and observed Cmax of FTD, TPI, or FTY exceeded the 
20 ms non-inferiority margin for QTcI, QTcF, QTcB, and 
uncorrected QT intervals (Fig. 4). Therefore, the observed 
pharmacokinetic concentrations of TAS-102 do not suggest 
a potential for clinically relevant QTc prolongation in this 
patient population.
However, at most, two placebo-adjusted changes from 
baseline in QTcI intervals at the time of maximum FTD 
concentration (1 patient), TPI concentration (2 patients), 
and FTY (1 patient) were >20 ms. Nothing could be found 
Table 1  continued Parameter Safety population (n = 44) Cardiac safety population (n = 30)
Number of prior regimens,b n (%)
 1 1 (2.3) 0
 2 10 (22.7) 7 (23.3)
 3 7 (15.9) 5 (16.7)
 ≥4 26 (59.1) 18 (60.0)
SD standard deviation; ECOG Eastern Cooperative Oncology Group
a Patients with multiple levels are counted in each applicable category
b Included all prior systemic therapies (neoadjuvant, adjuvant, metastatic)
Table 2  Comparison of least 
square mean placebo-adjusted 
change from baseline in 12-lead 
Holter QTcI (ms) between TAS-
102 and placebo
LS least square; CI confidence interval
a Repeated measures analysis of variance (ANOVA) model: change from baseline in QTcI result = Treat-
ment + Time + Treatment × Time. Compound symmetry covariance was used. Measurements at different 
time points within each patient’s treatment were treated as repeated measures
Day Postdose hour TAS-102 Placebo TAS-102 versus placebo
N LS meansa N LS meansa Difference 90 % CI
1 0 27 −1.9 27 −0.3 −1.6 (−5.6, 2.4)
0.25 27 −0.9 28 −1.6 0.7 (−3.3, 4.7)
0.5 29 −1.3 28 −4.0 2.7 (−1.2, 6.6)
1 29 −2.0 29 −2.2 0.2 (−3.7, 4.1)
2 28 −0.9 30 −0.6 −0.3 (−4.2, 3.6)
4 30 2.2 27 −1.9 4.1 (0.2, 8.1)
6 28 −3.4 29 −2.6 −0.8 (−4.8, 3.1)
8 28 −1.5 25 −3.3 1.8 (−2.3, 5.9)
10 28 −1.3 28 −3.5 2.2 (−1.7, 6.2)
12 21 −0.1 15 −4.9 4.8 (−0.3, 9.8)
12 0 26 −0.9 27 −0.4 −0.5 (−5.6, 4.5)
0.25 28 −1.3 28 −1.6 0.3 (−4.6, 5.2)
0.5 29 −1.8 28 −3.6 1.8 (−3.1, 6.7)
1 29 −3.3 29 −2.1 −1.1 (−6.0, 3.7)
2 28 −2.1 30 −0.6 −1.5 (−6.3, 4.4)
4 29 −0.4 27 −1.4 1.0 (−3.9, 5.9)
6 30 −3.4 29 −2.5 −1.0 (−5.7, 3.8)
8 27 0.3 25 −3.3 3.6 (−1.5, 8.7)
10 26 −3.9 28 −3.3 −0.7 (−5.7, 4.3)
12 19 0.2 15 −3.7 3.9 (−2.5, 10.3)
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in the medical history to explain these findings. However, 
the heart rates of one patient ranged from 63 to 99 bpm dur-
ing days 1 and 12, and from 69 to 89 bpm for the second 
patient during day 1 of cycle 1. By comparison, the mean 
heart rates of the remaining patients ranged from 73.6 to 
77.9 bpm during days 1 and 12. No patient experienced 
ventricular tachycardia or ventricular fibrillation, syncope, 
or seizure during the study.
Fig. 2  Plot of LS mean and 
one-sided 95 % CI for placebo-
adjusted change from baseline 
in 12-lead Holter QTcI over 
time on day 1 and day 12 of 
cycle 1 (cardiac safety popula-
tion)
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Fig. 3  Mean plasma concentra-
tion-time profiles after dosing of 
TAS-102: FTD (PK evaluable 
population). N = 40 for all time 
points on day 12, except at 12 h 
postdose (N = 39). FTD trif-
luridine, FTY trifluoromethyl-
2,4(1H,3H)-pyrimidinedione, 
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Fig. 4  Scatterplot of placebo-
adjusted change from baseline 
in QTcI interval from 12-lead 
Holter versus observed plasma 
FTD concentration for all 
patients (cardiac safety popula-
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Discussion
Using the same dosing regimen as in the recently com-
pleted RECOURSE phase 3 clinical trial [7], TAS-102 
caused no clinically relevant prolongation of the QTcI, 
QTcF, or QTcB intervals. The upper bounds of the one-
sided 95 % confidence interval for the largest time-matched 
mean effect of the drug on the QTc interval excludes 20 ms, 
which is different from the 10 ms defined by the Interna-
tional Council for Harmonisation, but was felt to be appro-
priate for this dedicated QTc study in a patient population 
with advanced solid tumors. Due to the cytotoxic nature of 
TAS-102, the typical “thorough QT/QTc study” design in 
healthy volunteers was not applicable. Considering the lim-
itation in the study design versus the potential benefit in a 
life-threatening indication, the threshold of 20 ms was con-
sidered acceptable for this dedicated QTc study in oncol-
ogy [11].
No cardiac safety concerns had been found in previous 
clinical trials, although some patients experienced adverse 
cardiac events, such as atrial flutter or atrial fibrillation [3, 
7, 12–14]. One patient in this study experienced a QTcI 
interval >500 ms on a single tracing following multiple-
dose administration, but this could not be confirmed due 
to low T-wave amplitude on the second and third trac-
ings. There were no morphological changes for T waves 
or U waves for any patients, and no patient experienced an 
adverse event of ventricular tachycardia, ventricular fibril-
lation, or syncope.
Based on the results of the linear mixed-effect model for 
the relation between plasma FTD, FTY, and TPI concen-
trations and the placebo-adjusted change from baseline in 
QTc intervals, no QT-prolonging effect was demonstrated. 
Cmax and AUC0–last of FTD increased approximately two- 
and threefold, respectively, compared with single-dose 
administration, suggesting an increase in the bioavailability 
and a decrease in the clearance of FTD with multiple-dose 
administration of TAS-102. The effect on the QT interval 
has been shown to be directly related to plasma levels of 
the drug or its main metabolites [15]. Therefore, in addition 
to negative results from time-matched analysis of QTcI in 
TAS-102 compared with placebo, exposure–response anal-
ysis, which was based on observed concentration of FTD, 
FTY, and TPI, also did not show a QT-prolonging effect.
In conclusion, there was no clinically relevant relation 
between plasma concentrations of TAS-102 and the QTc 
interval. In addition, TAS-102 had no clinically relevant 
effects on cardiac repolarization.
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